Fig. 2: The elevated METTL14 expression in patients with podocytopathies and injured podocytes in vitro. | Cell Death & Disease

Fig. 2: The elevated METTL14 expression in patients with podocytopathies and injured podocytes in vitro.

From: METTL14 aggravates podocyte injury and glomerulopathy progression through N6-methyladenosine-dependent downregulating of Sirt1

Fig. 2

A, B Representative images and quantification of immunohistochemical staining for METTL14 and WT1 on renal biopsy samples from normal subjects (n = 4) and patients with MCD (n = 6), FSGS (n = 6) and DN (n = 8). Scale bars, 20 μm. **P < 0.01 vs. normal subjects. C Quantitative RT-PCR and western blot analysis of METTL14 mRNA and protein expression in human cultured podocytes administrated with different doses of ADR (0.2−0.8 μg/ml) for 24 h (n = 6). D Quantitative RT-PCR and western blot analysis of METTL14 mRNA and protein levels in podocytes subjected to different doses of HG (25 or 35 mmol/l) for 24 h (n = 6). E Quantitative RT-PCR and western blot analysis of METTL14 mRNA and protein expression in podocytes treated with different doses of AGE (25−100 μg/ml) for 24 h (n = 6). F Representative confocal microscopic images of immunofluorescence staining for METTL14 in podocytes treated with ADR (0.4 μg/ml) or AGE (50 μg/ml) compared with normal controls. G Quantitative analysis of immunofluorescence staining for METTL14 in podocytes subjected to ADR (0.4 μg/ml) or AGE (50 μg/ml) in comparison to normal controls (n = 6). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. control group.

Back to article page